Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study
Matthias Rau, Kirsten Thiele, Niels‐Ulrik Korbinian Hartmann, Julia Möllmann, Stephanie Wied, Michael Böhm, Hubert Scharnagl, Winfried März, Nikolaus Marx, Michael Lehrke
Topics & Concepts
EmpagliflozinType 2 diabetesMedicinePlaceboInternal medicineRandomized controlled trialDiabetes mellitusEndocrinologyAlternative medicinePathologyDiabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patientsChronic Kidney Disease and Diabetes